Excellent outcome of acute lymphoblastic leukaemia with TCF3‐PBX1 rearrangement in Hong Kong. Issue 12 (26th July 2018)

• Record Type: Journal Article
• Authors: Lin, Anna; Cheng, Frankie W.T.; Chiang, Alan K.S.; Luk, Chung‐wing; Li, Rever C.H.; Ling, Alvin S.C.; Cheuk, Daniel K.L.; Chang, Kai‐on; Ku, Dennis; Lee, Vincent; Ha, Shau‐Yin; Li, Chi‐Kong
• Is Part Of: Pediatric blood & cancer. Volume 65:Issue 12(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-07-26
• Subjects: acute lymphoblastic leukaemia -- EFS -- survival -- t(1;19) -- TCF3‐PBX1; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.27346
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Objective: The aim of this study was to review clinical outcomes and prognosis of paediatric patients with acute lymphoblastic leukaemia (ALL) with TCF3‐PBX1 rearrangement. Patients: All children in Hong Kong diagnosed with ALL with TCF3‐PBX1 rearrangement over the past two decades were included. Methods: Six hundred and twenty‐four newly diagnosed patients with ALL from four consecutive studies were enrolled from 1997 to 2016. Patients carrying TCF3‐PBX1 rearrangement and patients at intermediate risk without the gene expression were compared for clinical characteristics, overall survival and event‐free survival (EFS). Results: The TCF3‐PBX1 rearrangement was detected in 30 of 624 patients (4.8%). Results were consistent across the consecutive clinical trials employed in the past two decades. Compared with 239 intermediate risk patients without TCF3‐PBX1 rearrangement, the 5‐year overall survival and EFS for patients with TCF3‐PBX1 rearrangement was superior, with both at 100% ( P = 0.12 and P = 0.029). Conclusion: This population‐based study over the past 20 years demonstrated that patients with TCF3‐PBX1 rearrangement had favourable EFS compared with other intermediate risk patients treated with a similar chemotherapy backbone.